This recombinant monoclonal antibody is designed as a research-grade biosimilar to Tazlestobart, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in various conditions, including autoimmune diseases and cancer, where tumor cells exploit this pathway to evade immune surveillance.
Tazlestobart represents a therapeutic antibody developed to modulate CTLA4 activity, with potential applications in oncology and immune-related disorders. This biosimilar provides researchers with a cost-effective tool for investigating CTLA4 biology, immune checkpoint mechanisms, and T-cell regulation in preclinical models. It enables studies exploring immune modulation strategies, tumor immunology, autoimmunity research, and the development of combination immunotherapy approaches.
Email: support@cusabio.com
Distributors Worldwide